Previously, we reported that MPT0L145 is a first-in-class PIK3C3/FGFR inhibitor that not only increases autophagosome formation due to FGFR inhibition but simultaneously perturbs autophagy flux via PIK3C3 inhibition in bladder cancer cells harboring aberrant fibroblast growth factor receptor (FGFR) activation [16,17]. The gene discussed is PIK3C3; the disease is urinary bladder cancer.